Effusanin e suppresses nasopharyngeal carcinoma cell growth by inhibiting NF-κB and COX-2 signaling

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Zhuang, Mingzhu ^a   Zhao, Mouming ^a   Qiu, Huijuan ^b   Shi, Dingbo ^b   Wang, Jingshu ^b   Tian, Yun ^b   Lin, Lianzhu ^a   Deng, Wuguo ^b  

^a SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM PYRROLIDINEDITHIOCARBAMATE; ANTIMITOTIC AGENT; CASPASE 3; CASPASE 9; CELECOXIB; CYCLOOXYGENASE 2; DITERPENOID; EFFUSANIN E; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN INHIBITOR; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DITERPENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BIOCHEMICAL COMPOSITION; CANCER INHIBITION; CARCINOMA CELL; CONTROLLED STUDY; DOWN REGULATION; DRUG DETERMINATION; DRUG EFFECT; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MALE; MOUSE; NASOPHARYNGEAL CARCINOMA CELL; NASOPHARYNX CARCINOMA; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RABDOSIA; RABDOSIA SERRA; TUMOR XENOGRAFT; ANIMAL; CARCINOMA; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; GENETICS; ISODON; METABOLISM; NASOPHARYNGEAL NEOPLASMS; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLOOXYGENASE 2; DITERPENES; HUMANS; ISODON; MALE; MICE; MICE, NUDE; NASOPHARYNGEAL NEOPLASMS; NF-KAPPA B; POLY(ADP-RIBOSE) POLYMERASES; SIGNAL TRANSDUCTION;

EID: 84908190353     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109951     Document Type: Article

References (31)

1. Wu E, Golitz LE (2000) Primary noncutaneous melanoma. Clin Lab Med 20: 731-744.
2. Busson P, Keryer C, Ooka T, Corbex M (2004) EBV-associated nasopharyngeal carcinomas, from epidemiology to virus-targeting strategies. Trends Microbiol 12: 356-360.
3. Xu Y, Zhang J, Shi W, Liu Y (2013) Anticancer effects of 3,3'-diindolylmethane are associated with G1 arrest and mitochondria-dependent apoptosis in human nasopharyngeal carcinoma cells. Oncol lett 5: 655-662.
4. Xiao WW, Huang SM, Han F, Wu SX, Lu LX, et al. (2011) Local Control, Survival, and Late Toxicities of Locally Advanced Nasopharyngeal Carcinoma Treated by Simultaneous Modulated Accelerated Radiotherapy Combined With Cisplatin Concurrent Chemotherapy Long-Term Results of a Phase 2 Study. Cancer 117: 1874-1883.
5. Huang J, Liang ZD, Wu TT, Hoque A, Chen H, et al. (2007) Tumorsuppressive effect of retinoid receptor-induced gene-1 (RRIG1) in esophageal cancer. Cancer Res 67: 1589-1593.
6. China Flora Editorial Committee of Flora of Chinese Academy of Sciences (1977) The flora of China: Beijing: Science Press. pp. 433-434.
7. Fang HY, Hsu CH, Chao CH, Wen ZH, Wu YC, et al. (2013) Cytotoxic and Anti-Inflammatory Metabolites from the Soft Coral Scleronephthya gracillimum. Mar Drugs 11: 1853-1865.
8. Nitoda T, Isobe T, Kubo I (2008) Effects of phenolic compounds isolated from Rabdosia japonica on B16-F10 melanoma cells. Phytother Res 22: 867-872.
9. Hu HZ, Yang YB, Xu XD, Shen HW, Shu YM, et al. (2007) Oridonin induces apoptosis via PI3K/Akt pathway in cervical carcinoma HeLa cell line. Acta Pharmacol Sin 28: 1819-1826.
10. Cui Q, Tashiro S, Onodera S, Minami M, Ikejima T (2007) Oridonin induced autophagy in human cervical carcinoma HeLa cells through Ras, JNK, and P38 regulation. J Pharmacol Sci 105: 317-325.
11. Kim JY, Kim HS, Kim YJ, Lee HK, Kim JS, et al. (2013) Effusanin C inhibits inflammatory responses via blocking NF-kB and MAPK signaling in monocytes. Int. Immunopharmacol 15: 84-88.
12. Sinicrope FA, Gill S (2004) Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev 23: 63-75.
13. Singh B, Lucci A (2002) Role of cyclooxygenase-2 in breast cancer. J Surg Res 108: 173-179.
14. Ghosh S, May MJ, Kopp EB (1998) NF-kB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16: 225-260.
15. De Bosscher K, Schmitz ML, Plaisance S, Vanden Berghe W, Fiers W, et al. (1997) Glucocorticoid-mediated repression of nuclear factor-kB-dependent transcription involves direct interference with transactivation. Proc Natl Acad Sci USA 94: 13504-13509.
16. Yin MJ, Yamamoto Y, Gaynor RB (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of IkB kinase-b. Nature 396: 77-80.
17. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB (1999) Sulindac inhibits activation of the NF-kB pathway. J Biol Chem 274: 27307-27314.
18. Lin L, Gao Q, Cui C, Zhao H, Fu L, et al. (2012) Isolation and identification of ent-kaurane-type diterpenoids from Rabdosia serra (MAXIM.) HARA leaf and their inhibitory activities against HepG-2, MCF-7, and HL-60 cell lines. Food Chem 131: 1009-1014.
19. Liu B, Wen JK, Li BH, Fang XM, Wang JJ, et al. (2011) Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms. Cell death Dis 2: 1-9.
20. Wang J, Xiao X, Zhang Y, Shi D, Chen W, et al. (2012) Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J Pineal Res 53: 77-90.
21. Kang CH, Chiang PH, Huang SC (2008) Correlation of COX-2 expression in stromal cells with high stage, high grade, and poor prognosis in urothelial carcinoma of upper urinary tracts. Urology 72: 153-157.
22. Deng WG, Zhu Y, Wu KK (2003) Up-regulation of p300 binding and p50 acetylation in tumor necrosis factor-alpha-induced cyclooxygenase-2 promoter activation. J Biol Chem 278: 4770-4777.
23. Hayden MS, Ghosh S (2008) Shared principles in NF-kappa B signaling. Cell 132: 344-362.
24. Mankan AK, Lawless MW, Gray SG, Kelleher D, McManus R (2009) NFkappa B regulation: the nuclear response. J Cell Mol Med 13: 631-643.
25. Baud V, Karin M (2009) Is NF-kappa B a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8: 33-40.
26. Karin M, Yamamoto Y, Wang QM (2004) The IKKNF-kappa B system: A treasure trove for drug development. Nat Rev Drug Discov 3: 17-26.
27. Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70: 461-477.
28. Leung CH, Grill SP, Lam W, Han QB, Sun HD, et al. (2005) Novel mechanism of inhibition of nuclear factor-kappa B DNA-binding activity by diterpenoids isolated from Isodon rubescens. Mol Pharmacol 68: 286-297.
29. Schmitz ML, Baeuerle PA (1991) The p65 subunit is responsible for the strong transcription activating potential of NF-kappa B. EMBO J 10: 3805-3817.
30. Ballard DW, Dixon EP, Peffer NJ, Bogerd H, Doerre S, et al. (1992) The 65-kDa subunit of human NF-kappa B functions as a potent transcriptional activator and a target for v-Rel-mediated repression. Proc Natl Acad Sci USA 89: 1875-1879.
31. Deng WG, Zhu Y, Montero A, Wu KK (2003) Quantitative analysis of binding of transcription factor complex to biotinylated DNA probe by a streptavidinagarose pulldown assay. Anal Biochem 323: 12-18.